Why Muse just added billions to Meta's market cap and to Mark Zuckerberg's net worth

Image
Why Muse just added billions to Meta's market cap and to Mark Zuckerberg's net worth Brian Sozzi Executive Editor Tue, September 22, 2026 at 6:12 AM PDT 3 min read META AAPL The way the market sees it now, Meta ( META ) is about to upend the enterprise tech market with its new Muse AI agent. "Lots can and will change in the future, but the key, simple point is that Meta has a hit on its hands with Muse," Evercore ISI Mark Mahaney said in a new note. Meta stock erupted, gaining 11.3% to close at $741.25 on Monday, adding a robust $192 billion to the company's market cap and more than $13 billion to CEO Mark Zuckerberg's net worth. The stock rose another 0.2% in premarket trading on Tuesday. Investor enthusiasm reached a fever pitch as Muse surged to the top spot on Apple's App Store. Muse reached 2.8 million downloads in its first 12 days across both the US and Canada app stores, according to Sensor Tower data. What's more, Muse has surpassed the early...

Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals

Chinese biopharma stocks jumped in Hong Kong on Monday after a report that the U.S. is considering rules that would allow American pharmaceutical companies to continue licensing most drugs from Chinese firms. Innovent Biologics jumped 6%, while Akeso surged 8% and CSPC Pharmaceutical Group gained more than 6%. HUTCHMED climbed 3%, while Sino Biopharmaceutical added 8%. The Hang Seng Biotech Index was also up more than 5%. The moves followed a Reuters report Friday, citing people briefed on the process, that the U.S. Treasury Department is drafting rules that would likely allow American pharmaceutical companies to invest in promising new drugs being developed by Chinese firms, excluding those related to pathogens or biotechnology that could be weaponized. The rules have not been finalized and remain subject to change, said the report. That would put biopharma on a different track from sectors such as artificial intelligence and semiconductors, where the U.S. has tightened restrictions on China. Almost half of U.S. deals to license drugs from overseas in 2025 were with Chinese companies, according to GlobalData, as cited by Reuters. Pfizer, for example, announced a partnership worth up to $10.5 billion with Innovent in May, covering the research and development of 12 oncology programs. China’s out-licensing boom has continued despite geopolitical concerns. A record 81 deals worth a combined $110 billion were completed in the first half of 2026, according to NMPA data cited by Nomura. The bank said investors now appear largely immune to intermittent geopolitical concerns around the sector, citing Chinese companies’ strong value proposition in novel drug development. China has also made globalization a key goal for pharmaceutical and biotech companies under its 15th five-year plan, Nomura noted. Against that backdrop, the bank expects China-U.S. out-licensing deals to ride on a high tide.

🔥 EXCLUSIVE PARTNER OFFER
Retro MP3 Car Radio Player 1 DIN Stereo EQ FM AM RDS DAB Receiver QC3.0 Bluetooth USB AUX Input For VW Porsche Mercedes Benz BMW

Retro MP3 Car Radio Player 1 DIN Stereo EQ FM AM RDS DAB Receiver QC3.0 Bluetooth USB AUX Input For VW Porsche Mercedes Benz BMW

Special Price

💥 Massive discount! Save big on this must-have item. Free shipping available!

Affiliate link — Commission earned at no extra cost to you

© EcoNews DZ — Global Economic & Financial News

Comments

Popular posts from this blog

Xi wants China to boost demand. Why isn’t it working?

It was billed as effortless London luxury. Then tenants found out the rules

'I didn't speak the Queen's English': Why people worry about their accents